ABO and carcinoma: Also discovered in patients with NMI carcinomas who had undergone TUR was that blood group A could affect the treatment outcome, whereas a lower incidence of disease recurrence and progression was found for blood group B.33According to a number of other authors, when bound on BC and ABO phenotype only, ABO antigens are not identified as appropriate biomarkers in BC outcome prognostication.34, 35